Skip to search formSkip to main contentSkip to account menu

ENMD-1198

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
SummaryBackground 2-methoxyestradiol (2ME2) is an estradiol-17β metabolite with antiproliferative and antiangiogenic activities… 
2011
2011
Preclinical Development 2-Methoxyestradiol Analogue ENMD-1198 Reduces Breast Cancer-Induced Osteolysis and Tumor Burden Both In Vitro and In Vivo
It has been estimated that 70% of advanced breast cancer patients will face the complication of bone metastases. Three processes… 
2010
2010
ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties
The formation of a new vascular network by angiogenesis is a key driver in tumor growth and metastasis, making this an attractive… 
2010
2010
Abstract 4418: ENMD-1198, a new microtubule-targeting agent with potent anti-vascular properties
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC The formation of a new vascular network, by a… 
2009
2009
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
2009
2009
A single-center, open-label, dose escalation, safety, and pharmacokinetic study of ENMD-1198 administered orally to patients (pts) with advanced cancer.
3562 Background: ENMD-1198 (2-methoxyestra-1, 3, 5, (10) 16-tetraene-3-carboxamide), an analog of 2-methoxyestradiol (2ME2), has… 
Review
2008
Review
2008
Author's response to reviews Title: ENMD-1198, a novel tubulin-binding agent reduces HIF-1 and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in…
Christian Moser (christian.moser@klinik.uni-regensburg.de) Sven A Lang (sven.lang@klinik.uni-regensburg.de) Akira Mori (akr@kuhp… 
2007
2007
ENMD-1198 in Combination with Vincristine Shows Synergistic Activity in Leukemia Cells and Prolonged Mouse Survival in Human Leukemia Xenografts.
ENMD-1198 (2-methoxyestra-1, 3, 5, (10), 16-tetraene-3-carboxamide), an analogue of 2 methoxyestradiol (2ME2 or Panzem®), is a… 
2007
2007
Metabolism and pharmacokinetics of the 2ME2 Analog, ENMD-1198, an orally bioavailable microtubule destabilizing agent, in rats, dogs, and humans
B99 Background: Clinical studies of 2-methoxyestradiol (2ME2, Panzem ® ), a microtubule destabilizing agent, demonstrate an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)